407 General Discussion Figure 2.1. Continued. 1STOPP D5 comprised 5.2% (n = 181/3465) of all generated STOPP signals in all OPERAM trial sites (Switzerland, Belgium, Ireland and the Netherlands). 2Percentage of accepted signals by the pharmacotherapy team with the number of generated STOPP D5 signals (n = 181) as the denominator in all OPERAM trial sites 3A subanalysis in Dutch OPERAM patients revealed that 44% of recommendations to discontinue long-term use of a benzodiazepine based on STOPP D5 were not agreed upon, primarily due to patient reluctance [44]. 4The implementation of STOPP/START-based recommendations was calculated at two months after discharge with the number of recommendations based on STOPP D5 as the denominator. 5Based on results fromWoolcott et al (2009) [62]. The Bayesian unadjusted odds ratio OR) estimate for benzodiazepine use on falls was 1.57 (95% CI, 1.43–1.72) and the adjusted OR was 1.41 (95% CI, 1.20–1.71) in patients >60 years. DRA = drug related hospital admission; NNH = number needed to harm; OR = odds ratio. 5
RkJQdWJsaXNoZXIy MTk4NDMw